Spero Therapeutics (SPRO) to Release Quarterly Earnings on Thursday

Spero Therapeutics (NASDAQ:SPRO) is scheduled to announce its earnings results after the market closes on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter.

Spero Therapeutics (NASDAQ:SPRO) last announced its quarterly earnings results on Monday, August 5th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. The company had revenue of $10.20 million during the quarter, compared to analysts’ expectations of $9.80 million. Spero Therapeutics had a return on equity of 25.67% and a net margin of 14.74%. During the same quarter in the previous year, the firm earned ($0.23) earnings per share. On average, analysts expect Spero Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Spero Therapeutics Stock Performance

Shares of NASDAQ SPRO opened at $1.27 on Friday. The business’s 50-day simple moving average is $1.30 and its 200-day simple moving average is $1.37. Spero Therapeutics has a 52 week low of $1.01 and a 52 week high of $1.89. The firm has a market cap of $68.57 million, a price-to-earnings ratio of 3.97 and a beta of 0.63.

Analyst Ratings Changes

SPRO has been the subject of a number of analyst reports. TD Cowen upgraded shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Spero Therapeutics in a report on Tuesday, August 6th. Finally, HC Wainwright cut their target price on shares of Spero Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Monday.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.